跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Bryce Alan Kiberd Bryce
Postdoctoral Fellow
Dalhousie University
,
Biochemistry, Genetics and Molecular Biology
电子邮件
BB033100
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=56883033100
h-index
h10-index
h5-index
5966
引用
39
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
737
引用
14
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
98
引用
7
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
1989 …
2023
每年的科研成果
综述
指纹
网络
科研成果
(152)
相似简介
(6)
指纹
深入其中 Bryce Alan Kiberd Bryce 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Medicine and Dentistry
ACE Inhibitor
14%
Acute Graft Rejection
15%
Adverse Event
7%
Allograft
12%
Antihypertensive Agent
6%
Basiliximab
8%
Cardiovascular Disease
11%
Charlson Comorbidity Index
8%
Chronic Kidney Disease
16%
Cohort Analysis
10%
Contraindication
9%
Creatinine
9%
Cyclosporine
16%
Daclizumab
8%
Delayed Graft Function
6%
Diabetes
9%
Diabetes Mellitus
19%
Disease
10%
Drug Therapy
11%
Emergency Department
6%
End Stage Renal Disease
39%
Frailty
13%
Glomerular Filtration Rate
12%
Graft Failure
21%
Graft Survival
21%
Hazard Ratio
7%
Health Care Cost
28%
Hemodialysis
10%
Hyperlipidemia
6%
Immunosuppressive Treatment
16%
Ischemia
8%
Kidney Allograft
10%
Kidney Allograft Rejection
8%
Kidney Graft
100%
Kidney Transplantation
63%
Life Expectancy
13%
Microalbuminuria
11%
Nephrology
8%
Nephropathy
30%
Organ Donor
7%
Outpatient
9%
Patient Referral
15%
Polyomavirus
9%
Population
7%
Prevalence
9%
Prospective Study
9%
Proteinuria
7%
Quality Adjusted Life Year
20%
Renal Failure
21%
Transplantation
65%
Keyphrases
Acid Exposure
9%
Acute Rejection
11%
Angiotensin-converting Enzyme Inhibitor (ACEi)
8%
Basiliximab
10%
Chronic Kidney Disease
6%
Cold Ischemia
7%
Confidence Interval
5%
Cyclosporine
9%
Dialysis
11%
Dialysis Efficiency
5%
Dialysis Initiation
7%
Donor-recipient Matching
5%
End-stage Renal Disease
10%
Hemodialysis Patients
8%
In-center Hemodialysis
5%
Kidney
5%
Kidney Transplant
18%
Kidney Transplant Recipients
6%
Kidney Transplantation
23%
Mycophenolic Acid
8%
Neoral
6%
Panel-reactive Antibody
5%
Renal Allograft Rejection
8%
Transplant Survival
8%
Transplantation
6%
Warm Ischemia Time
8%
Nursing and Health Professions
Clinician
7%
Cohort Analysis
5%
Cold Ischemia
9%
Contraindication
8%
End Stage Renal Disease
12%
Frailty
8%
Graft Failure
7%
Graft Survival
8%
Hemodialysis
13%
Ischemia
8%
Kidney Graft
42%
Kidney Transplantation
20%
Panel Reactive Antibody
9%
Quality Adjusted Life Year
6%
Transplantation
25%
